Showing results (131-140 of 192) with videos related to
Sort By:
Pageof 20
Blood|March 8, 2007
Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptorsPearlie K Epling-Burnette, Fanqi Bai, Jeffrey S Painter, et al.Cancer|September 3, 2011
A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndromeAzra Raza, Naomi Galili, Scott E Smith, et al.American Journal of Hematology|August 19, 2015
Comparing the prognostic value of risk stratifying models for patients with lower-risk myelodysplastic syndromes: Is one model better?Amer M Zeidan, Mikkael A Sekeres, Xiao-Feng Wang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 11, 2009
Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignanciesHideki Makishima, Heather Cazzolli, Hadrian Szpurka, et al.Scientific Reports|March 29, 2020
Association of immunophenotype with expression of topoisomerase II α and β in adult acute myeloid leukemiaAndrew P Michelson, Shannon McDonough, Cheryl L Willman, et al.Blood|February 3, 2011
Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignanciesRamon V Tiu, Lukasz P Gondek, Christine L O'Keefe, et al.Leukemia & Lymphoma|June 4, 2011
Telomere length in myelodysplastic syndromesDana E Rollison, P K Epling-Burnette, Jong Y Park, et al.American Journal of Hematology|February 15, 2016
Autoimmune diseases and myelodysplastic syndromesRami S Komrokji, Austin Kulasekararaj, Najla H Al Ali, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2009
Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemiaPierre Fenaux, Ghulam J Mufti, Eva Hellström-Lindberg, et al.Nature Cell Biology|April 7, 2020
Loss of lenalidomide-induced megakaryocytic differentiation leads to therapy resistance in del(5q) myelodysplastic syndromeSergio Martinez-Høyer, Yu Deng, Jeremy Parker, et al.Pageof 20